Labcorp Holdings IncNYSE: LH
Health Care · Health Care Services
$256.24
-0.22%
Vol: 446K
Research Digest
Friday, May 1, 2026
Labcorp beats Q1 estimates with 3.3% EPS upside and raised full-year adjusted EPS guidance
Labcorp delivered strong Q1 2026 results with revenue of $3.54 billion (+5.8% YoY) and adjusted EPS of $4.25, 3.3% above consensus. Diagnostics segment grew 5.0% and biopharma lab services grew 8.2%. Raised full-year adjusted EPS guidance to $18.03 midpoint. Announced pediatric diagnostics collaboration with CHOP and genomic testing partnership with Illumina. LaunchPad AI and robotics initiative enhancing operational efficiency.
Previous Market Intelligence
13 daysApr 30Labcorp reported Q1 2026 revenue of $3.54B (up 5.8% YoY) and adjusted EPS of $4.25 beating consensus of $4.09, and raised full-year guidance to $14.73B revenue expected.Positive▶
Labcorp beat Q1 expectations with revenue of $3.54B (up 5.8% YoY) and adjusted EPS of $4.25 (vs. $4.09 est.). The company raised full-year guidance to $14.73B revenue and margin expanded 30+ bps to 14.4% in enterprise adjusted operating margin. Key strategic initiatives include launch of AI-powered real-world data platform with AWS in mid-April 2026. Specialty testing portfolio in neurology and oncology continues rapid expansion. Stock up 2.64% in pre-market on results. Average analyst PT is $311.33 representing 19.17% upside with 9 Buy ratings.
Apr 29LabCorp launches fentanyl urine test (April 15) and AI platform with AWS (April 14); Evercore raises price target from $280 to $300 on April 8Positive▶
LabCorp announced multiple product launches and strategic initiatives in recent days. On April 15, company launched Labcorp Fentanyl Urine Visual Test. On April 14, launched new AI-powered real-world data platform with AWS. On April 8, analyst Evercore ISI raised price target from $280 to $300. Company previously announced FDA-cleared blood test for Alzheimer's disease assessment in primary care settings and strategic investment in new 500,000 sq ft Central Laboratory facility in Indiana (construction to begin 2026). In 2025, LabCorp grew revenue over 7% with double-digit adjusted EPS growth and strong free cash flow. FY26 guidance set at $17.55–$18.25 EPS. Q1 earnings due soon (before market open on April 29). Declared quarterly dividend of $0.72 per share.
Apr 16Labcorp forecasts Q1 2026 earnings on April 30; beat Q4 expectations with $4.07 adjusted EPS vs. $3.95 consensus.Positive▶
Labcorp Holdings reported Q4 2025 adjusted EPS of $4.07, beating Wall Street expectations of $3.95, with full-year 2025 revenue growth over 7% and double-digit adjusted EPS growth. Q1 2026 financial results will be announced on April 30, 2026 at 9:00 a.m. ET. The company increased its dividend 7.5% to $0.86 per quarter, marking 15 consecutive years of increases. Labcorp launched the first FDA-cleared blood test for Alzheimer's assessment and partnered with Roche for automated mass spectrometry. A new $500,000 square foot Indiana Central Laboratory facility is planned for construction in 2026. Piper Sandler raised price target to $300 from $270.
Apr 15LabCorp raises Q1 earnings guidance and expands clinical partnerships; Q1 2026 results due April 30.Positive▶
LabCorp Holdings will release Q1 2026 financial results on April 30 before market open. Q4 2025 adjusted EPS of $4.07 beat expectations of $3.95. The company secured a new $750 million term loan and expanded collaboration with Illumina on oncology testing. Piper Sandler raised price target to $300 from $270 but maintained Hold.
Apr 14LabCorp partnered with Childrens Hospital of Philadelphia on pediatric diagnostics; Q1 earnings due April 30.Positive▶
LabCorp announced strategic collaboration with CHOP to accelerate pediatric diagnostic discovery and nationwide availability. Declared $0.72 quarterly dividend payable June 11. Q1 2026 earnings April 30 before market open. Diagnostic sector saw mixed performance.
Apr 13Labcorp reports FY25 revenue growth of 7.25% to $13.95B; Q1 2026 earnings due April 30 with raised dividend.Positive▶
Labcorp reported strong FY 2025 revenue of $13.95B (up 7.25% YoY) with earnings of $876.50M (up 17.49%). Q1 2026 earnings April 30. Expanded Illumina collaboration for oncology testing. PathAI platform FDA-clearance deployment. Quarterly dividend raised to $0.72. Consensus Buy with PT $308.30.
Apr 10LabCorp Q1 2026 Earnings April 30; Declares $0.72 DividendPositive▶
Q1 results before market open April 30. Declared $0.72 quarterly dividend. Piper Sandler raised target to $300.
Apr 9LabCorp Q1 2026 earnings scheduled for April 30 amid strong growth outlookPositive▶
LabCorp reported robust 2025 results with 7%+ revenue growth and double-digit adjusted EPS growth. The company issued 2026 guidance of 4.7-6.0% revenue growth and adjusted EPS of $17.55-$18.25. Q1 2026 earnings will be released April 30, with analysts expecting continued growth. Piper Sandler raised its price target to $300 on February 24, 2026, supporting a Buy consensus rating.
Apr 8Labcorp launches first FDA-cleared blood test for Alzheimer's disease assessment in primary care.Positive▶
Labcorp Q4 revenue +7% with double-digit adjusted EPS growth. Launched first FDA-cleared blood test for Alzheimer's in primary care. Piper Sandler raised PT to $300. New $750M term loan.
Apr 7Labcorp Holdings Expands Oncology Testing and Secures $750M LoanPositive▶
Labcorp Holdings secured $750 million term loan in March 2026 and expanded collaboration with Illumina to broaden oncology testing access. Company also partnered with PathAI on FDA-cleared pathology platform. Expected Q4 2025 earnings growth of 6.6% revenue and 15% EPS increase. Piper Sandler raised price target to $300 from $270 on February 24.
Apr 6Labcorp launches Alzheimer's blood test and expands Illumina oncology collaborationPositive▶
Labcorp launched the first FDA-cleared blood test for Alzheimer's disease assessment in primary care settings, enabling wider access and improved early evaluation. The company expanded precision oncology collaboration with Illumina on March 18, 2026 to develop and distribute NGS-based cancer tests. Labcorp announced construction of new 500,000 sq ft Central Laboratory in Indiana with Q1 2026 results on April 30. 2025 revenue grew over 7% with double-digit adjusted EPS growth. 2026 guidance: $14.61-$14.79B revenue.
Apr 3Labcorp Holdings exceeded Q4 EPS estimates but missed revenue; secured $750M term loan and expanding oncology testing with Illumina.Mixed▶
Labcorp exceeded Q4 2025 EPS at $4.07 versus $3.93 but missed revenue at $3.52B versus $3.56B, resulting in 7.19% stock decline. Secured a new $750 million term loan and expanded collaboration with Illumina for oncology testing. 2026 forecasts 5.4% revenue growth and ~9% adjusted EPS growth.
Apr 2Labcorp secures $750 million term loan and expands Illumina oncology partnership ahead of Q1 2026 earnings April 30.Positive▶
Labcorp Holdings secured a new $750 million term loan in March 2026 and expanded its collaboration with Illumina to broaden access to next-generation sequencing based cancer testing and co-develop precision oncology diagnostics. The company reported strong full-year 2025 results with revenue of $13.95 billion (+7.25% YoY) and earnings of $876.50 million (+17.49% YoY). Q4 2025 EPS of $4.07 beat consensus estimates of $3.95 (3.13% surprise). The company will announce Q1 2026 results on April 30, 2026. Piper Sandler raised price target to $300 from $270 with a Hold rating on February 24. The company operates nearly 70,000 employees and performs 700+ million tests annually.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.